Medicare Enrolled
Dr. Angela Alistar, MD
Hematology & Oncology · Winston Salem, NC
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Alistar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Alistar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Alistar
Dr. Angela Alistar is a hematology & oncology specialist in Winston Salem, NC, with 17 years of NPI registration. Based on federal Medicare data, Dr. Alistar performed 1,222 Medicare services across 600 unique beneficiaries.
Between the years covered by Open Payments, Dr. Alistar received a total of $432,911 from 70 pharmaceutical and/or device companies across 901 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Alistar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 15% volume in NC
$432,911 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,222
Medicare services
Top 15% in NC for hematology & oncology
600
Unique beneficiaries
$64
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~72 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
278 | $68 | $240 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
209 | $8 | $15 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
192 | $8 | $20 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
175 | $109 | $363 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
77 | $110 | $449 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
75 | $151 | $487 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
71 | $76 | $247 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
35 | $42 | $129 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
35 | $102 | $343 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
29 | $71 | $332 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
27 | $135 | $551 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
19 | $50 | $150 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$432,911
Total received (2018-2024)
Avg $61,844/year across 7 years
Top 3% in NC for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
70
Companies
901
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$410,931 (94.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$14,956 (3.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,024 (1.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$91,423
2023
$98,949
2022
$84,180
2021
$66,958
2020
$24,991
2019
$44,501
2018
$21,909
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$40,427
E.R. Squibb & Sons, L.L.C.
$39,298
Merck Sharp & Dohme LLC
$7,513
Takeda Pharmaceuticals U.S.A., Inc.
$2,779
Daiichi Sankyo Inc.
$252
Novartis Pharmaceuticals Corporation
$231
PFIZER INC.
$190
Mirati Therapeutics, Inc.
$93
PharmaEssentia USA Corporation
$84
Lilly USA, LLC
$75
GlaxoSmithKline, LLC.
$71
Eisai Inc.
$52
ARRAY BIOPHARMA INC
$44
Astellas Pharma US Inc
$43
Exelixis Inc.
$42
Janssen Biotech, Inc.
$38
EMD Serono, Inc.
$34
Stemline Therapeutics Inc.
$34
GENZYME CORPORATION
$22
Bayer Healthcare Pharmaceuticals Inc.
$19
Regeneron Healthcare Solutions, Inc.
$18
Cumberland Pharmaceuticals, Inc.
$17
TAIHO ONCOLOGY, INC.
$16
Pharmacosmos Therapeutics Inc.
$16
Genentech USA, Inc.
$15
Top 3 companies account for 95.4% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$213,932
Merck Sharp & Dohme LLC
$69,938
AstraZeneca Pharmaceuticals LP
$63,716
Merck Sharp & Dohme Corporation
$57,966
Seagen Inc.
$11,193
Exelixis Inc.
$3,592
Celgene Corporation
$3,055
Takeda Pharmaceuticals U.S.A., Inc.
$2,870
Novartis Pharmaceuticals Corporation
$755
Daiichi Sankyo Inc.
$684
PFIZER INC.
$531
Amgen Inc.
$374
Janssen Biotech, Inc.
$331
Mirati Therapeutics, Inc.
$281
Eisai Inc.
$229
EISAI INC.
$223
GlaxoSmithKline, LLC.
$205
Incyte Corporation
$195
PharmaEssentia USA Corporation
$192
Lilly USA, LLC
$171
Sirtex Medical Inc
$154
Regeneron Healthcare Solutions, Inc.
$151
Genentech USA, Inc.
$133
Karyopharm Therapeutics Inc.
$125
Bayer HealthCare Pharmaceuticals Inc.
$120
Astellas Pharma US Inc
$110
Foundation Medicine, Inc.
$110
Ipsen Biopharmaceuticals, Inc
$108
JAZZ PHARMACEUTICALS INC.
$105
GENZYME CORPORATION
$95
Boehringer Ingelheim Pharmaceuticals, Inc.
$71
EMD Serono, Inc.
$65
AbbVie, Inc.
$64
F. Hoffmann-La Roche AG
$61
Rigel Pharmaceuticals, Inc.
$57
AbbVie Inc.
$54
ARRAY BIOPHARMA INC
$51
TAIHO ONCOLOGY, INC.
$50
Emmaus Medical, Inc.
$43
Jazz Pharmaceuticals Inc.
$43
Janssen Pharmaceuticals, Inc
$42
Kyowa Kirin, Inc.
$42
Lexicon Pharmaceuticals, Inc.
$39
Puma Biotechnology, Inc.
$39
Bayer Healthcare Pharmaceuticals Inc.
$39
Stemline Therapeutics Inc.
$34
Collegium Pharmaceutical, Inc.
$33
ABBVIE INC.
$31
Taiho Oncology, Inc.
$30
Pharmacosmos Therapeutics Inc.
$28
Dova Pharmaceuticals
$28
Heron Therapeutics, Inc.
$28
Covidien LP
$27
Acrotech Biopharma LLC
$25
Blueprint Medicines Corporation
$17
TerSera Therapeutics LLC
$17
MorphoSys, US Inc.
$17
Cumberland Pharmaceuticals, Inc.
$17
Myriad Genetic Laboratories, Inc.
$16
Apellis Pharmaceuticals, Inc.
$16
Pharmacyclics LLC, An AbbVie Company
$15
Spectrum Pharmaceuticals Inc.
$15
Advanced Accelerator Applications
$15
Acceleron Pharma, Inc.
$15
Pharmacyclics LLC, an AbbVie Company
$15
EUSA Pharma (US) LLC
$14
Seattle Genetics, Inc.
$14
Alexion Pharmaceuticals, Inc.
$14
Helsinn Therapeutics (U.S.), Inc.
$13
Array BioPharma Inc.
$12
Top 3 companies account for 80.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AYVAKIT · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CHANTIX · CINVANTI · COSELA · CREON · CYRAMZA · Cabometyx · Creon · Cresemba · DARZALEX · Doptelet · ELIQUIS · ENHERTU · ERBITUX · ERLEADA · Empaveli · Endari · Enhertu · Erleada · FARESTON · FOUNDATIONONE · FRUZAQLA · Fabhalta · Folotyn · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · LigaSure · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · NERLYNX · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OJJAARA · OPDIVO · Orserdu · PADCEV · PLUVICTO · POTELIGEO · PROMACTA · Padcev · Prolia · REBLOZYL · RYDAPT · Reblozyl · Revlimid · Rezlidhia · SANCUSO · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · Stivarga · Sylvant · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TEPMETKO · TRUSELTIQ · TUKYSA · Tavalisse · ULTOMIRIS · VENCLEXTA · VERZENIO · VPRIV · VYXEOS · Venclexta · Vyloy · XALKORI · XARELTO · XPOVIO · Xermelo · Xofigo · Xospata · Xtampza ER · ZEJULA · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (95%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for hematology & oncology in NC.
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Alistar is a clinical cardiology specialist, with above-average Medicare volume (top 15% in NC), with speaking/promotional industry engagement in the top 3% of NC peers, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Alistar experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Alistar performed 278 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Alistar receive payments from pharmaceutical companies?
Yes. Dr. Alistar received a total of $432,911 from 70 companies across 901 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Alistar's costs compare to other hematology & oncology specialists in Winston Salem?
Dr. Alistar's average Medicare payment per service is $64. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Alistar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Winston Salem
Browse hematology & oncology specialists in Winston Salem ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NC
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NC
Which NC hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology